Metropolitan Life Insurance Company (MetLife)’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-9,460	Closed	-$120K	–	2606
2020 Q4	$120K	Hold	9,460	–	–	﹤0.01%	2262
2020 Q3	$92.9K	Hold	9,460	–	–	﹤0.01%	2257
2020 Q2	$94.1K	Hold	9,460	–	–	﹤0.01%	2289
2020 Q1	$83.6K	Buy	+9,460	New	+$93.3K	﹤0.01%	2144
2019 Q4	–	Sell	-7,553	Closed	-$44.4K	–	2577
2019 Q3	$44.4K	Hold	7,553	–	–	﹤0.01%	2508
2019 Q2	$90.6K	Hold	7,553	–	–	﹤0.01%	2356
2019 Q1	$91.2K	Hold	7,553	–	–	﹤0.01%	2364
2018 Q4	$94.8K	Buy	7,553 +1,205	+19%	+$16.6K	﹤0.01%	2312
2018 Q3	$94.2K	Hold	6,348	–	–	﹤0.01%	2483
2018 Q2	$107K	Hold	6,348	–	–	﹤0.01%	2284
2018 Q1	$145K	Hold	6,348	–	–	﹤0.01%	2089
2017 Q4	$164K	Buy	+6,348	New	+$128K	﹤0.01%	2021
2017 Q3	–	Sell	-12,976	Closed	-$181K	–	2545
2017 Q2	$181K	Buy	+12,976	New	+$191K	﹤0.01%	2397
2016 Q3	–	Sell	-11,833	Closed	-$133K	–	2656
2016 Q2	$133K	Hold	11,833	–	–	﹤0.01%	2567
2016 Q1	$162K	Hold	11,833	–	–	﹤0.01%	2291
2015 Q4	$224K	Hold	11,833	–	–	﹤0.01%	2180
2015 Q3	$222K	Hold	11,833	–	–	﹤0.01%	2220
2015 Q2	$176K	Buy	+11,833	New	+$180K	﹤0.01%	2478

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CNCE Position: Q1 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 9,460 shares — an estimated $120K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CNCE in Q2 2015 and held it in 18 quarters. The position peaked at $224K in Q4 2015. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

Metropolitan Life Insurance Company (MetLife) reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 9,460 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $120K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Concert Pharmaceuticals, Inc. in Q2 2015 and held it in 18 quarters.
Metropolitan Life Insurance Company (MetLife)'s Concert Pharmaceuticals, Inc. position peaked at $224K in Q4 2015.
91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2021, filed 14 May 2021.